Skip to content

Consequences of COVID 19 Pandemic on Childhood Asthma

Consequences of SARS-CoV2 Pandemic on Childhood Asthma Control and Exacerbations: French Multicenter Cross-sectional VIRASTHMA COVID G4 Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04821908
Acronym
VIRASTHCOVID
Enrollment
577
Registered
2021-03-30
Start date
2021-09-14
Completion date
2025-03-31
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma in Children

Keywords

Asthma control, COVID-19 pandemic, Respiratory infection, Environmental pollution

Brief summary

The SARS-CoV2 pandemic, which emerged in the first quarter of 2020, has led to an unprecedented health crisis in our modern healthcare systems and has resulted in strong national public health measures. The impact of the pandemic and its indirect environmental consequences on pediatric asthma is currently being assessed. In particular, the study of its role on the risk of exacerbations and modification of control is one of the priority research objectives defined by European societies. The primary aim is to study the impact of the pandemic on asthma control in children aged 3-16 years with a medical diagnosis of asthma, compared to data from other observational cohorts conducted in the same region prior to the pandemic. A sub-population of children 3-16 years will be assessed at exacerbation and at a follow-up visit, 2-4 months later, with clinical data, biological and microbiological samples.

Detailed description

Children aged 3-16 years with a medical diagnosis of asthma, will be assessed for asthma control, exacerbation rate. Data will be compared to data from other observational cohorts conducted in the same region prior to the pandemic. A sub-population of children 3-16 years will be assessed at exacerbation and at a follow-up visit, 2-4 months later, with clinical data, biological and microbiological samples.

Interventions

None listed

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

* Children and adolescents aged 3 to 16 years old * With a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months, * Assessed in one of the pediatric departments participating in the study, * After written consent of at least one of the 2 parents and/or representative of the parental authority, and of the child if he is older than 8 years old. Criteria for the sub-population assessed at "exacerbation" and second visit: * Children and adolescents aged 3 to 16 years * With a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months, * Hospitalized for a severe asthma exacerbation (requiring hospitalization and general corticosteroid therapy) at Lille University Hospital * After written consent of both parents and/or representative of the parental authority, and of the child if he is over 8 years old

Exclusion criteria

* History of chronic respiratory disease other than asthma, * Inability of parents to receive informed information, inability to participate in the entire study, refusal to sign the consent form

Design outcomes

Primary

MeasureTime frameDescription
Controlled asthmaat inclusionComposite criteria defined by a cACT (4-11 years) or ACT (12-16 years) score ≥ 20 and according to GINA criteria.

Secondary

MeasureTime frameDescription
Characteristics of asthmaAt inclusion and follow-up visit at 2-4 months for the sub-population included at exacerbationComposite criteria : allergic phenotype, severity assessed by GINA treatment level, number of exacerbations in the past year, lung function
history of SARS-Cov2 infection in the past yearAt inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbationhistory of SARS-Cov2 infection based on patient report
number of infectious episodes in the past yearAt inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbationnumber of infectious episodes based on patient report
ObservanceAt Inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbationAssessed by four-items Morisky-Green questionnaire : 1/ Do you ever forget to take your medication; 2/ Are you careless sometimes about taking your medication 3/ When you feel better, do you sometimes stop taking your medication 4/ Sometimes, if you feel worse when you take your medication, do you stop taking it. An answer "no" to any of the 4 questions is considered as "not well-observed medication".
QoL (Quality of life) in children aged 7-17 yearsAt Inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbationAssessed by PAQLQ : PAEDIATRIC ASTHMA QUALITY OF LIFE QUESTIONNAIRE. The PAQLQ has 23 questions in 3 domains (symptoms, activity limitation and emotional function). The activity domain contains 3 'patient-specific' questions. Children are asked to think about how they have been during the previous week and to respond to each of the 32 questions on a 7-point scale (7 = not bothered at all - 1 = extremely bothered). The overall PAQLQ score is the mean of all 23 responses and the individual domain scores are the means of the items in those domains. The highest the score is, the better QoL is.
Outdoor levels of pollutants and pollensAt Inclusion and Follow-up visit at 2-4 months for the sub-population included at exacerbationComposite criteria : monthly average measurements of CO, O3, NO, NO2, SO2, PM2.5, PM10 and pollen counts
Respiratory virus infection (SARS-CoV2 and other)at exacerbation and at follow-up visit at 2-4 months for the sub-population included at exacerbationResults of viral PCR

Countries

France

Contacts

PRINCIPAL_INVESTIGATORStéphanie Lejeune, MD

University Hospital, Lille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026